Tyra Biosciences annual free cash flow
2020
2021
2022
2023
2024
2025
Tyra Biosciences Free Cash Flow (FCF) History (TYRA)
Tyra Biosciences reported −$95.3M in free cash flow for fiscal 2025, a decrease of $24.8M from the previous fiscal year.
View full Tyra Biosciences company overviewTyra Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$95.3M | −$24.8M | — | — |
| 2024 | 2024-12-31 | −$70.4M | −$19.5M | — | — |
| 2023 | 2023-12-31 | −$50.9M | −$65,000 | — | — |
| 2022 | 2022-12-31 | −$50.8M | −$26.4M | — | — |
| 2021 | 2021-12-31 | −$24.4M | −$16.3M | — | — |
| 2020 | 2020-12-31 | −$8.1M | — | — | — |
Tyra Biosciences quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$31.1M | −$7.4M | — | — |
| Q1 2026 | 2026-03-31 | −$32.7M | −$7.2M | — | — |
| Q4 2025 | 2025-12-31 | −$23.7M | −$4.1M | — | — |
| Q3 2025 | 2025-09-30 | −$22.4M | −$4.5M | — | — |
| Q2 2025 | 2025-06-30 | −$23.7M | −$13.0M | — | — |
| Q1 2025 | 2025-03-31 | −$25.5M | −$3.3M | — | — |
| Q4 2024 | 2024-12-31 | −$19.6M | −$5.5M | — | — |
| Q3 2024 | 2024-09-30 | −$17.9M | −$722,000 | — | — |
| Q2 2024 | 2024-06-30 | −$10.7M | −$1.1M | — | — |
| Q1 2024 | 2024-03-31 | −$22.2M | −$12.3M | — | — |
| Q4 2023 | 2023-12-31 | −$14.1M | −$2.1M | — | — |
| Q3 2023 | 2023-09-30 | −$17.2M | −$5.0M | — | — |
| Q2 2023 | 2023-06-30 | −$9.7M | $7.8M | — | — |
| Q1 2023 | 2023-03-31 | −$9.9M | −$724,000 | — | — |
| Q4 2022 | 2022-12-31 | −$12.0M | −$2.9M | — | — |
| Q3 2022 | 2022-09-30 | −$12.3M | −$6.4M | — | — |
| Q2 2022 | 2022-06-30 | −$17.4M | −$12.7M | — | — |
| Q1 2022 | 2022-03-31 | −$9.2M | −$4.4M | — | — |
| Q4 2021 | 2021-12-31 | −$9.1M | — | — | — |
| Q3 2021 | 2021-09-30 | −$5.8M | — | — | — |
| Q2 2021 | 2021-06-30 | −$4.7M | — | — | — |
| Q1 2021 | 2021-03-31 | −$4.7M | — | — | — |
Tyra Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$8.1M to −$95.3M, a net decrease of $87.2M. Tyra Biosciences's latest reported quarter, Q2 2026, generated −$31.1M in free cash flow, a decrease of $7.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tyra Biosciences filings at SEC.gov ↗